STOCK TITAN

Rafael Holdings (RFL) Stock News, Mar-Jun 2021

RFL NYSE

Rafael Holdings, Inc. reports developments as a biotechnology company focused on pharmaceutical development and interests in clinical-stage and early-stage pharmaceutical and medical device companies. Its lead program is Trappsol® Cyclo™, a hydroxypropyl-beta-cyclodextrin product candidate evaluated for Niemann-Pick Disease Type C1, with additional cyclodextrin-related work in neurodegenerative disease.

Recurring company news covers clinical development of Cyclo Therapeutics programs, scientific presentations, patent and licensing activity, quarterly and annual financial results, and governance changes. Updates also address the company’s consolidated expenses following the Cyclo Therapeutics acquisition and its portfolio interests in healthcare and medical-device development.

Rhea-AI Summary

Rafael Holdings, Inc. (NYSE: RFL) and Rafael Pharmaceuticals presented at the Raymond James 2021 Human Health Innovation Conference on June 22, 2021. Key figures included CEO Ameet Mallik and President Sanjeev Luther. The companies are focused on developing novel cancer therapies, particularly through Rafael Pharmaceuticals, which is advancing multiple clinical studies for its lead drug, CPI-613 (devimistat). This includes ongoing Phase 3 trials for metastatic pancreatic cancer and acute myeloid leukemia. The companies aim to create a publicly traded late-stage clinical oncology entity, enhancing their market position.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.46%
Tags
none
-
Rhea-AI Summary

Rafael Holdings, Inc. (NYSE: RFL) has announced a merger with Rafael Pharmaceuticals, a late-stage oncology firm specializing in cancer metabolism therapeutics. The merger, unanimously approved by both boards, aims to create a publicly traded company focused on innovative cancer treatments. Key figures include Howard Jonas as Chairman and Ameet Mallik as CEO. The merger includes the acquisition of Altira Capital for $30 million and requires a capital raise of at least $50 million. The lead drug, CPI-613 (devimistat), is in Phase 3 trials for metastatic pancreatic cancer, with results expected in Q4 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
-
Rhea-AI Summary

Rafael Holdings, Inc. (NYSE: RFL) reported Q3 FY 2021 revenue of $1.0 million, down from $1.2 million year-over-year, primarily due to asset sales and reduced parking revenues amid the COVID pandemic. The loss per share was $0.15, compared to $0.14 in the prior year. The company appointed Ameet Mallik as CEO and William Conkling as Chief Commercial Officer. A shelf registration statement for up to $250 million of Class B common stock was filed. Rafael Pharmaceuticals anticipates pivotal trial data for pancreatic cancer in Q4 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.13%
Tags
Rhea-AI Summary

Rafael Holdings, Inc. (NYSE: RFL) announced the appointment of three new members to its Board of Directors: Ameet Mallik, CEO; Shannon Thyme Klinger, Chief Legal Officer of Moderna; and Mark McCamish, CEO of IconOVir Bio. Chairman Howard Jonas expressed optimism, stating the new board members bring significant expertise to advance the company's oncology pipeline. Ameet Mallik highlighted the importance of their industry experience in maximizing the potential of their therapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.13%
Tags
management
-
Rhea-AI Summary

Rafael Holdings, Inc. (NYSE: RFL) announced a grant of 908,497 restricted shares of Class B common stock to CEO Ameet Mallik on May 27, 2021, as part of his employment agreement. The shares will vest over the next few years, with initial shares vesting on May 6, 2022, followed by monthly vesting until April 2025. This stock grant was made under the company's 2018 Equity Incentive Plan and approved by the Compensation Committee, serving as an inducement for Mr. Mallik's hiring which took effect on May 1, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags
none
-
Rhea-AI Summary

Rafael Pharmaceuticals will present two posters at the 2021 ASCO Annual Meeting from June 4-8, discussing trials on devimistat for pancreatic and biliary tract cancers. Presentation Abstract #TPS4158 explores the efficacy of gemcitabine and cisplatin, while Abstract #TPS4176 focuses on devimistat paired with (m)FOLFIRINOX. Sanjeev Luther, the company’s President, emphasizes significant advancements despite challenges. Devimistat, a first-in-class compound, targets cancer cell metabolism, showing promise for future cancer treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.13%
Tags
conferences
Rhea-AI Summary

Rafael Holdings, Inc. (NYSE: RFL) announced an inducement grant on April 15, 2021, to Chief Commercial Officer William Conkling for options to purchase 118,409 shares of Class B common stock. The exercise price is set at $40.85, reflecting the closing price on the previous trading day. The options will vest over a period, starting with 29,602 on April 15, 2022, followed by monthly vesting. This grant is part of Rafael's 2018 Equity Incentive Plan, designed to attract key talent while adhering to NYSE Rule 303A.08.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.54%
Tags
none
-
Rhea-AI Summary

Rafael Pharmaceuticals has announced the enrollment of over 150 patients in its Phase 3 clinical trial (ARMADA 2000) for relapsed or refractory acute myeloid leukemia (AML). This multicenter trial evaluates the efficacy of CPI-613® (devimistat) in combination with specific chemotherapy drugs. The company recently achieved FDA fast-track designation for this treatment, highlighting its potential in addressing the urgent need for effective AML therapies. Experts emphasize the significance of this milestone in improving outcomes for patients suffering from this challenging cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.70%
Tags
-
Rhea-AI Summary

Rafael Holdings, Inc. (NYSE: RFL) reported Q2 FY 2021 revenue of $1.0 million, down from $1.2 million year-over-year, primarily due to the sale of a building. Loss per share increased to $0.50, influenced by a $7.0 million impairment related to Altira. Ameet Mallik will assume the CEO role on May 1, 2021. The firm holds 51% of Rafael Pharmaceuticals, which has received FDA Fast Track designation for its lead compound, CPI-613® (devimistat), aimed at treating various cancers. The company continues its focus on oncology through strategic investments and partnerships.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
Rhea-AI Summary

Rafael Holdings, Inc. (NYSE: RFL) has appointed Ameet Mallik as its new Chief Executive Officer, effective May 1, 2021, succeeding founder Howard Jonas who remains Chairman. Bill Conkling joins as Chief Commercial Officer on March 15, 2021. Mallik, previously from Novartis, brings extensive experience in oncology, crucial as Rafael conducts multiple clinical studies. The leadership expansion aims to enhance the company's ability to develop innovative cancer therapies across its subsidiaries, including Rafael Pharmaceuticals and LipoMedix.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.00%
Tags
none

FAQ

What is the current stock price of Rafael Holdings (RFL)?

Rafael Holdings (RFL) last closed at $0.9871.

What is the market cap of Rafael Holdings (RFL)?

The market cap of Rafael Holdings (RFL) is approximately $51.5M.